title: Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell.
abstract: Tyroserleutide (YSL) is an active, low-molecular-weight polypeptide, comprised of three amino acids, that has shown antitumor effects on human hepatocarcinoma BEL-7402 in vitro and in vivo. In this study, we evaluated the inhibition of YSL on invasion and adhesion of the mouse B16-F10 melanoma cell line by injecting B16-F10 cells into the tail veins of C57BL/6 mice to establish an experimental lung metastasis model. YSL inhibited B16-F10 cell metastasis to lung, reducing the number and area of metastasis lesions. When we treated B16-F10 cells with YSL (0.01, 0.1, 1, 10, or 100 microg/mL) in vitro, we found that YSL inhibited the proliferation of B16-F10 cells with a 28.11% rate of inhibition. YSL significantly decreased the adhesiveness of B16-F10 cells to Matrigel with a 29.15% inhibition rate; YSL also significantly inhibited the invasion of B16-F10 cells, producing an inhibition of 35.31%. By analyses with Western blot and real-time RT-PCR, we found that YSL markedly inhibited the expression of ICAM-1 in B16-F10 cells. These data suggest that YSL inhibits the growth, invasion, and adhesion of B16-F10 cells.
authors.affiliation: The College of Pharmaceuticals and Biotechnology, Tianjin University, Tianjin, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yao
authors.forename: Xu-Chun
authors.initials: XC
authors.lastname: Che
authors.forename: Rong
authors.initials: R
authors.lastname: Lu
authors.forename: Min-Na
authors.initials: MN
authors.lastname: Zheng
authors.forename: Zhi-Feng
authors.initials: ZF
authors.lastname: Zhu
authors.forename: Jin-Ping
authors.initials: JP
authors.lastname: Li
authors.forename: Xu
authors.initials: X
authors.lastname: Jian
authors.forename: Lin-Xi
authors.initials: LX
authors.lastname: Shi
authors.forename: Jun-Yan
authors.initials: JY
authors.lastname: Liu
authors.forename: Wen-Yuan
authors.initials: WY
authors.lastname: Gao
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005260:Female; D007797:Laminin / Q000378:metabolism; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary*; D008546:Melanoma, Experimental / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008970:Molecular Weight; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D011509:Proteoglycans / Q000378:metabolism; D011897:Random Allocation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014184:Transplantation, Homologous; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D007797:Laminin; D009842:Oligopeptides; D011509:Proteoglycans; C059485:matrigel; D003094:Collagen; C484773:H-Tyr-Ser-Leu-OH